Leading Fosamax,Zometa,Actonel Side Effects Lawyers. Why Clients Choose Us.

HOME PAGE

We don't
get paid unless you win!

We take pharmaceutical product liability cases on a contingency fee basis –
you pay
NO ATTORNEY FEES unless
we recover compensation for you.

Powell Law Firm, L.C.

FOSAMAX^®, ZOMETA^®, AREDIA^®, ACTONEL^®
These drugs have been linked to Osteonecrosis of the
jaw (also known as "Dead Jaw", "BisPhossy Jaw" and
"Jaw Necrosis").
If you or a loved one have taken any of these
“Bisphosphonates” and suffered from necrosis of the jawbone, Osteonecrosis of the Jaw (ONJ) or other jaw bone problems or side effects, you may be due compensation.

Bisphosphonates Jaw Osteonecrosis Articles

"Expert Panel Recommendations for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws: June 2004"

http://www.ada.org/prof/resources/topics/topics
osteonecrosis_whitepaper.pdf

This pamphlet outlines the symptoms of Osteonecrosis of the Jaw (ONJ) and the different procedures doctors may perform in order to make an accurate diagnosis. The pamphlet also provides a list of factors that may increase one’s risk of developing ONJ, as well as how to manage the disease and treat patients with ONJ.

Http://www.fda.gov/medwatch/SAFETY
/2004/safety04.htm#zometa

This website will direct you to the US Food and Drug Administration’s Zometa Osteonecrosis of the Jaw Safety Alert, first posted on September 30, 2004.

http://www.fda.gov/medwatch/
SAFETY/2004/ZometaHCP.pdf

This September 2004 letter was sent from Novartis to doctors, making them aware of the changes they recently made to the Aredia and Zometa US package inserts, now including a precautionary statement regarding a possible risk of developing Osteonecrosis of the Jaw (ONJ).

http://www.fda.gov/medwatch/
SAFETY/2004/Zometa_PI.pdf

(In particular pages 9-11, 20)
In August 2004, Novartis revised the product information label for Zometa, adding the risk of developing Osteonecrosis of the Jaw (ONJ) to their list of precautions, as well as to their Post-Marketing Experience notes.

"Coping with Cancer: Dental Health and Osteonecrosis of the Jaw"

http://www.us.novartisoncology.com/
info/coping/dental_health.jsp

The Novartis Oncology website provides an overview of what a person’s dental hygiene
routine should include if he or she has cancer. It also discusses the risk of developing osteonecrosis of the jaw and the factors that may increase the risk. Finally, it provides information regarding diagnosis and treatment.

"Pamidronate (Aredia) and Zoledronate (Zometa) Induced Avascular Necrosis of the Jaws: A Growing Epidemic

Robert E. Marx, Letter to the Editor, Journal of Oral Maxillofacial Surgery. 61:1115-1118, 2003

Robert E. Marx, Letter to the Editor.pdf

Dr. Marx’s letter describes his study of 36 Osteonecrosis of the Jaw (ONJ) cases. He explains how he reached the conclusion that a connection exists between ONJ and bisphosphonates. He describes common ONJ symptoms and how bisphosphonates may affect the jawbone’s ability to regrow. He concludes his letter by discussing methods of prevention and possible treatments for Osteonecrosis of the Jaw (ONJ).

"Bisphosphonates and Osteonecrosis of the jaw"
Patrick M Purcell and Ian W Boyd, Australian Health Review, eMJA (Medical Journal of Australia)

https://www.mja.com.au/public/issues/
182_08_180405/pur10144_fm.html

This article provides the clinical characteristics of 13 Osteonecrosis of the Jaw (ONJ) patients, reported to the Adverse Drug Reactions Advisory Committee (ADRAC). It provides the patients’ age and sex, which bisphosphonate(s) they were treated with and why, how long they were receiving bisphosphonate therapy before the onset of their ONJ, and their related symptoms.

ADA.org: A-Z Topics: Osteonecrosis of the Jaw

http://www.ada.org/prof/resources/
topics/osteonecrosis.asp

This article provides information regarding dental management for patients currently receiving intravenous bisphosphonate therapy. It also includes a link to a document providing information on obtaining informed consent regarding the risks associated with long-term bisphosphonate use.

"Osteonecrosis of the Jaw"

http://courses.washington.edu/bonephys/opjawON.html

This article provides a simple overview of ONJ and includes a detailed picture of exposed necrotic bone. It also includes simple graphs displaying incidence of ONJ in cancer patients taking a variety of bisphosphonates and a graph showing incidence of Osteonecrosis of the Jaw (ONJ) after prolonged bisphosphonate use.

"Bisphosphonates May Put Patients At Risk For Deterioration Of The Jaw, American Association of Endondontists"
Medical News Today, April 3, 2006

http://www.medicalnewstoday.com/
medicalnews.php?newsid=40774

This article explains the American Association of Endodontists’ position statement regarding the recent findings regarding ONJ and bisphosphonates. The AAE consider themselves at the forefront of this emerging Osteonecrosis of the Jaw (ONJ) problem based on the fact that endodontists are experts at finding the cause of oral and facial pain that has been difficult to diagnose. The article explains the AAE’s recommendations to those individuals currently taking bisphosphonates and those individuals that think they may be experiencing ONJ symptoms.

"Jaw Disease Found in Patients Using Cancer Drug"
Miguel Sanchez, Oral Cancer Foundation, March 6, 2006

http://www.oralcancerfoundation.org/
news/story.asp?newsId=640

While this article discusses general information regarding Osteonecrosis of the Jaw (ONJ) and the effects of prolonged bisphosphonate use, it also provides an outline of the medical reasons why bisphosphonates, meant to strengthen bones, can actually have an adverse affect on individuals’ jawbones.

Marx, Robert. Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention and Treatment. J Oral Maxillofac Surg 2005; 63 (11): 1567-75.

Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws

Dr. Marx presents a detailed article regarding his study of 119 ONJ patients, all who were treated with either oral or intravenous bisphosphonates. He presents all of his findings, which demonstrate that there exists a direct correlation between ONJ and the use of bisphosphonates. The article includes Dr. Marx’s recommendations for preventing and treating Osteonecrosis of the Jaw (ONJ). The article contains many pictures of exposed bone, tissue loss, drainage, x-rays of bone loss, and pictures of infected, non-healing areas where extractions occurred.

"Jaw Ailment Shows Industry Moves Slowly on Drug Warnings"
Geeta Anana, The Wall Street Journal Online, Health, December 8, 2004.

http://online.wsj.com/public/resources/
documents/SB110245057172293526.htm

Anana’s article describes Dr. Ruggiero’s research and findings regarding his 90 bisphosphonate related ONJ cases. The article also focuses on Novartis’ position on the link between Osteonecrosis of the Jaw (ONJ) and Aredia and Zometa, as of December 2004. Anana describes what steps the company has taken to issue warnings, how it plans to continue investigating the problem, and what it plans to do in the future.

"Drug Linked to Death of Jawbone"
Rita Rubin, USA TODAY, Health and Behavios, March 13, 2005

http://www.usatoday.com/
news/health/2005-03-13-jawbone-deaths_x.htm

This article is a report on Dr. Salvatore Ruggiero’s findings regarding the link between bisphosphonates and ONJ. The article explains the effects that long-term use of bisphosphonates may have on the body based on the fact that the drugs may remain in bones for years after individuals stop taking them

Having trouble viewing the documents? You need to download Adobe Acrobat Reader. It's simple and it's free - just click on the link below and follow the downloading instructions.

http://www.adobe.com/products/
acrobat/readstep2.html

We have formed an unprecedented team
of experienced lawyers that can represent
you against the big drug companies

We believe that drug companies who place profit above
people must be held accountable for their negligence
and the damage they cause to innocent victims' lives.
We have fearlessly combatted and won cases against
some of the largest corporations in the world.

What Makes Us Unique
Our ability to try cases sets us apart from
other law firms. Many firms do not have the desire or the experience to take the final step in the litigation process.

Our ability to take a case to trial gives our clients a
significant edge in two important aspects.

First, we prepare cases with an eye to trial needs,
avoiding unnecessary delays.

Second, our ability to go to trial allows us to negotiate a
settlement, if appropriate, from a position of strength.
We will not settle a case unless our attorneys
are confident that a satisfactory result has been obtained.

Finally, we know that privacy is of utmost importance
to our clients. From your first inquiry,
we are committed to safeguarding your identity,
your case and your concerns.

To talk with a member
of our team please complete the
Online Information Form
or call us at
1-866-429-0715

Click Here
to Email Us

Our Home Page

We are representing individuals
throughout the United States and Internationally.